U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07227233) titled 'Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.' on Nov. 10.
Brief Summary: The goal of this clinical trial is to learn if an artificial intelligence model will be able to select patients with advanced breast cancer who may respond to a second cyclin-dependent kinase 4/6 (CDK4/6) inhibitor after they have progressed on the first CDK4/6 inhibitor. Patients for this study need to have hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
The main questions the study aims to answer are:
If the artificial intelligence model...